| __timestamp | Exelixis, Inc. | Madrigal Pharmaceuticals, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 50829000 | 15746000 |
| Thursday, January 1, 2015 | 57305000 | 13392000 |
| Friday, January 1, 2016 | 116145000 | 9290000 |
| Sunday, January 1, 2017 | 159362000 | 7672000 |
| Monday, January 1, 2018 | 206366000 | 15293000 |
| Tuesday, January 1, 2019 | 228244000 | 22648000 |
| Wednesday, January 1, 2020 | 293355000 | 21864000 |
| Friday, January 1, 2021 | 401715000 | 37318000 |
| Saturday, January 1, 2022 | 459856000 | 48130000 |
| Sunday, January 1, 2023 | 542705000 | 108146000 |
| Monday, January 1, 2024 | 492128000 |
Igniting the spark of knowledge
In the competitive landscape of biotechnology, understanding financial trends is crucial. Over the past decade, Exelixis, Inc. and Madrigal Pharmaceuticals, Inc. have shown distinct trajectories in their Selling, General, and Administrative (SG&A) expenses. Exelixis has seen a remarkable increase, with expenses growing nearly tenfold from 2014 to 2023, peaking at approximately $543 million. This reflects a strategic expansion and investment in operational capabilities. In contrast, Madrigal Pharmaceuticals, while also increasing its SG&A expenses, has maintained a more conservative growth, with a fourfold rise to about $108 million in the same period. This divergence highlights differing business strategies, with Exelixis aggressively scaling operations, while Madrigal adopts a more measured approach. These trends offer valuable insights into each company's market positioning and future potential.
SG&A Efficiency Analysis: Comparing Johnson & Johnson and Exelixis, Inc.
Operational Costs Compared: SG&A Analysis of Amgen Inc. and Exelixis, Inc.
Bio-Techne Corporation or Madrigal Pharmaceuticals, Inc.: Who Manages SG&A Costs Better?
Exelixis, Inc. or Ultragenyx Pharmaceutical Inc.: Who Manages SG&A Costs Better?
Operational Costs Compared: SG&A Analysis of Exelixis, Inc. and Merus N.V.
Cost Management Insights: SG&A Expenses for Exelixis, Inc. and HUTCHMED (China) Limited
Comparing SG&A Expenses: Exelixis, Inc. vs Novavax, Inc. Trends and Insights
SG&A Efficiency Analysis: Comparing Exelixis, Inc. and MiMedx Group, Inc.
Cost Management Insights: SG&A Expenses for Madrigal Pharmaceuticals, Inc. and Alpine Immune Sciences, Inc.
Cost Management Insights: SG&A Expenses for Madrigal Pharmaceuticals, Inc. and Iovance Biotherapeutics, Inc.
Madrigal Pharmaceuticals, Inc. and Geron Corporation: SG&A Spending Patterns Compared
Madrigal Pharmaceuticals, Inc. or Viridian Therapeutics, Inc.: Who Manages SG&A Costs Better?